Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic

Jeffrey B Schwimmer1, Jethro S Johnson2, Jorge E Angeles3

  • 1Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla, California; Department of Gastroenterology, Rady Children's Hospital San Diego, San Diego, California.

Gastroenterology
|July 1, 2019
PubMed

Insights

The intestinal microbiome in children with nonalcoholic fatty liver disease (NAFLD) shows reduced diversity and specific bacterial changes linked to disease severity. These gut microbiome alterations may indicate NAFLD progression and serve as diagnostic markers.

Area of Science:

  • Pediatric Gastroenterology
  • Microbiome Research
  • Hepatology

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent in children.
  • The intestinal microbiome's role in NAFLD development and severity is under investigation.

Purpose of the Study:

  • To analyze and compare the fecal microbiomes of children with and without NAFLD.
  • To identify specific microbial and functional alterations associated with NAFLD and its severity in pediatric populations.

Main Methods:

  • Prospective, observational, cross-sectional study of 87 children with NAFLD and 37 controls.
  • 16S rRNA amplicon and metagenomic shotgun sequencing of fecal samples.
  • Analysis of microbial taxa and bacterial pathways using statistical modeling and gene set enrichment analysis.

Main Results:

  • Children with NAFLD exhibited lower fecal microbiome alpha-diversity compared to controls.
  • Nonalcoholic steatohepatitis (NASH) was associated with the lowest alpha-diversity.
  • Increased Prevotella copri abundance correlated with more severe fibrosis; lipopolysaccharide biosynthesis genes were enriched in NASH microbiomes.
  • Models incorporating liver enzymes and specific microbial genes accurately identified NASH and fibrosis severity.

Conclusions:

  • Pediatric NAFLD and NASH are associated with intestinal dysbiosis.
  • Gut microbiome alterations, including increased inflammatory bacterial products, may contribute to NAFLD pathogenesis.
  • Intestinal microbiome profiles could serve as potential biomarkers for NAFLD diagnosis and severity assessment.
Abstract

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.9K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
188
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
740
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
485
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
36.7K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
263